Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Halozyme Therapeutics

Evaluate

Thumbnail
July 13, 2023

Pharma finds a way to gain weight

In the second quarter it paid to be a leading obesity company. As for Covid, not so much.

Thumbnail
April 27, 2023

One subcutaneous form goes, but the Opdivo dream continues

Article image
Vantage logo
April 06, 2023

The Covid crash continues

Pfizer keeps declining, but it is not the only pandemic player to suffer.

Article image
Vantage logo
March 16, 2023

Biologics look set to lose US drug price negotiation loophole

Article image
Vantage logo
January 17, 2023

Biopharma's stock market winners of 2022 revealed

Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.

Article image
Vantage logo
November 02, 2022

If at first... pharma’s most drawn-out development timelines revealed

Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.

Article image
Vantage logo
August 02, 2022

Roche tries to jump ahead with subcutaneous Tecentriq

Article image
Vantage logo
July 05, 2022

Takeout spend ticks up

M&A is back on the menu, but there are still reasons to be cautious.

Article image
Vantage logo
April 13, 2022

Takeover-driven resurgence fails to materialise for biotech

Deal making in biosimilars dominates a slow start to the year for biopharma M&A.

Article image
Vantage logo
April 13, 2022

Halozyme ups potential to deliver with Antares

Article image
Vantage logo
March 22, 2022

Argenx takes a step towards convenience

The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up